Preclinical data on MD Anderson Cancer Center-developed drug offers hope for Imbruvica-resistant mantle cell lymphoma patients
First approved in 2013 for relapsed/refractory mantle cell lymphoma (MCL), J&J’s Imbruvica is now being used as the first line of defense for the rare, aggressive, incurable form of non-Hodgkin lymphoma. However, some patients do not respond to the treatment — which scientists attribute to underlying intrinsic or acquired drug resistance. Now, researchers at the University of Texas MD Anderson Cancer Center may have developed a drug that could help Imbruvica-resistant patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.